AKAP9 anticorps (AA 17-130)

N° du produit ABIN968571

Cet anticorps anti-AKAP9 est un anticorps Souris Monoclonal détectant AKAP9 dans WB et IF. Adapté pour Humain. Ce Primary Antibody a été cité dans 3+ publications.

Aperçu rapide pour AKAP9 anticorps (AA 17-130) (ABIN968571)

Antigène: AKAP9 (A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp AKAP9 est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF)

Clone: 7-AKAP450

Détail du produit anti-AKAP9 anticorps

Épitope: AA 17-130

Attributs du produit: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Human AKAP450 aa. 17-130

Isotype: IgG1

Information d'application

Commentaires:

Related Products: ABIN968537, ABIN967389

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 250 μg/mL

Buffer: Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store undiluted at -20°C.

Références pour anticorps anti-AKAP9 (ABIN968571)

Westphal, Tavalin, Lin, Alto, Fraser, Langeberg, Sheng, Scott: "Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex." dans: Science (New York, N.Y.), Vol. 285, Issue 5424, pp. 93-6, (1999) (PubMed).

Witczak, Skålhegg, Keryer, Bornens, Taskén, Jahnsen, Orstavik: "Cloning and characterization of a cDNA encoding an A-kinase anchoring protein located in the centrosome, AKAP450." dans: The EMBO journal, Vol. 18, Issue 7, pp. 1858-68, (1999) (PubMed).

Lin, Wyszynski, Madhavan, Sealock, Kim, Sheng: "Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1." dans: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 18, Issue 6, pp. 2017-27, (1998) (PubMed).

Détails sur AKAP9

Antigène: AKAP9 (A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9))

Autre désignation: AKAP450

Sujet: Compartmentalization of the type II cAMP-dependent protein kinase (PKA) within the cell is essential for its discrete physiological effects. PKA localization is mediated by interactions between the regulatory (RII) subunit and A-kinase anchoring proteins (AKAPs) which position PKA in close proximity to relevant substrates. Some AKAPs exhibit tissue specific expression, while others are detected ubiquitously. AKAP450 localizes PKA type II to centrosomes. The N-terminal portion of AKAP450 (amino acids 1-1626) is almost identical to the Yotiao protein (~210 kDa), an AKAP that localizes PKA to NMDA receptors. In addition, AKAP450 contains three major regions (cc1, cc2, cc3) of coiled coil structures, which are characteristic features of centrosomeal proteins. It is expressed at low levels in multiple tissues, including skeletal muscle and liver, but is highly expressed in kidney. PKA is thought to be involved in the maintenance of the interphase microtubule network and to be necessary for stabilization of minus-end microtubules that originate from the centrosome. Thus AKAP450 may serve as a scaffolding protein to localize PKA and other signaling molecules together in cetrosomes. This antibody is routinely tested by western blot analysis.

Poids moléculaire: 450 kDa

Pathways: M Phase, SARS-CoV-2 Protein Interactome